Apremilast
- Generic Name
- Apremilast
- Brand Names
- Otezla, Apremilast Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O7S
- CAS Number
- 608141-41-9
- Unique Ingredient Identifier
- UP7QBP99PN
- Background
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the tr...
- Indication
Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Active Psoriatic arthritis, Ulceration of the mouth
- Associated Therapies
- -
Apremilast in the Treatment of Uveitis
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 3
- Registration Number
- NCT00889421
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00521339
- Locations
- 🇺🇸
Oregon Medical Research Center, P.C., Portland, Oregon, United States
🇺🇸Central Dermatology, Saint Louis, Missouri, United States
🇺🇸Tufts-New England Medical Center Hospitals, Boston, Massachusetts, United States
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 204
- Registration Number
- NCT00456092
- Locations
- 🇬🇧
Chapel Allerton Hospital, Leeds, United Kingdom
🇬🇧Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
🇨🇦Credit Valley Rheumatology, Mississauga, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.